Tenax Therapeutics, Inc.
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| cardiovascular | ×0.70 | 3 |
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 3 disclosed transactions, Tenax Therapeutics, Inc. concentrates its licensing activity in Cardiovascular. Tenax Therapeutics, Inc. pays a 0.70x discount to market median, with the strongest premiums in Cardiovascular (0.70x). Their most common deal structure is License, with an average disclosed value of $47M. Most recent activity: 2024.
Premium by therapeutic area
How Tenax Therapeutics, Inc. pays relative to peer medians in each TA
Pipeline coverage & gaps
Tenax Therapeutics, Inc. has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 2 | — | $60M |
| Acquisition | 1 | — | $22M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2024 | Levosimendan (oral and subcutaneous formulations) | Orion Corporation | pulmonary hypertension associated with HFpEF (PH-HFpEF) | phase_3 | — | $60M |
| 2024 | levosimendan | Orion Corporation | PH-HFpEF | phase_3 | — | $60M |
| 2021 | Imatinib | PH Precision Med | pulmonary arterial hypertension | phase_2 | — | $22M |
How this is computed
For each Tenax Therapeutics, Inc. deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.149, clamped to [0.7, 1.5].